ASCO19: 5-year data shows that pembrolizumab increases survival rates for certain NSCLC patients

Five-year data from the Phase 1B KEYNOTE-001 clinical trial has demonstrated that pembrolizumab increases overall survival for advanced non-small-cell lung patients (aNSCLC). “These data are similar to what we have seen in other cancers treated with immunotherapy in that there are a population of patients who can live for five years or more. It’s truly remarkable that for more patients than ever before, we no longer have to count survival in months,” commented David Graham (Levine Cancer Institute, NC, USA). Specifically, 23.2% of people who had not previously been treated with chemotherapy and 15.5% of previously-treated patients were alive after 5...